Mount Sinai Health System is leveraging an AI powered platform to enhance genomic testing speed and streamline cancer care workflows, enabling faster diagnosis and improved precision oncology outcomes.

Glimpse:

Announced in April 2026, Mount Sinai partnered with SOPHiA GENETICS to deploy the SOPHiA DDM platform across its oncology and pathology workflows. The AI-driven system analyzes complex genomic data to accelerate test turnaround times, reduce manual workload, and improve interpretation of cancer-related genetic variants.

Mount Sinai Health System has begun implementing an AI-powered platform to enhance genomic testing capabilities and improve cancer care delivery. The initiative is part of a collaboration with SOPHiA GENETICS, a company specializing in AI-driven precision medicine solutions.

The platform, SOPHiA DDM, integrates artificial intelligence to analyze complex genomic and multimodal data, enabling faster and more accurate interpretation of cancer related genetic information. This helps clinicians make quicker and more informed decisions in precision oncology.

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center, treats more than 4,000 oncology patients annually. By adopting this platform, the organization aims to streamline molecular pathology workflows, reduce bottlenecks, and significantly improve turnaround times for genomic testing

A key advantage of the system is its connection to a global intelligence network of over 800 healthcare institutions. This allows clinicians to compare genomic variants against large datasets, enhancing the accuracy of mutation interpretation and supporting more precise treatment strategies.

The AI platform also reduces the need for manual data analysis by consolidating multiple steps in the genomic testing pipeline. This enables pathology teams to focus more on clinical decision-making and patient care rather than time consuming data processing tasks.

Early results indicate that the system has already reduced hands on analysis time and improved testing efficiency, helping clinicians deliver faster and more effective care. This is particularly important amid ongoing workforce shortages in pathology, which have been a major challenge in cancer diagnostics.

Overall, the adoption of AI-driven genomic platforms like SOPHiA DDM reflects a broader shift toward data driven, precision oncology, where faster insights can directly translate into better patient outcomes and more personalized treatment approaches.